Oncology
6 drugs are in development for Prostate Cancer.
- Companies
- 6
- Clinical trials
- 226
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Prostate Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| proclarix | Onconetix, Inc. (ONCO) |
Phase 3(1)
| Drug | Company |
|---|---|
| BXCL701 | BioXcel Therapeutics, Inc. (BTAI) |
Phase 2(1)
| Drug | Company |
|---|---|
| ngm120 | NGM BIOPHARMACEUTICALS INC (NGM) |
Phase 1(2)
| Drug | Company |
|---|---|
| JANX007 | Janux Therapeutics, Inc. (JANX) |
| NUV-868 | Nuvation Bio Inc. (NUVB) |
Phase 4(1)
| Drug | Company |
|---|---|
| Lu-17-PSMA-617 | Novartis AG (NVS) |
About this indication
Prostate Cancer context
Oncology·MeSH: Prostatic Neoplasms (D011471)
Narrower concept of MeSH descriptor Prostatic Neoplasms
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Prostate Cancer?
BioSniper tracks 6 drugs in development for Prostate Cancer across 6 companies.
How many clinical trials target Prostate Cancer?
There are 226 clinical trials targeting Prostate Cancer tracked by BioSniper.
What is the prevalence of Prostate Cancer?
The estimated prevalence of Prostate Cancer is approximately 256.0 per 100,000 population.